Advocacy intelligence hub — real-time data for patient organizations
Mayo Clinic — EARLY_PHASE1
National Institute of Neurological Disorders and Stroke (NINDS) — NA
University Hospital, Basel, Switzerland — NA
University of California, Los Angeles — PHASE2
Mayo Clinic
Hospices Civils de Lyon
Huashan Hospital — NA
Isturisa: FDA approved
ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing®s disease for whom pituitary surgery is not an option or has not been curative.
Centre Hospitalier Universitaire de Nīmes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Patient Assistance Programs1
Isturisa
Recordati Rare Diseases
Isturisa
(osilodrostat)Orphan drugRecordati Rare Diseases, Inc
12.1 Mechanism of Action Osilodrostat is a cortisol synthesis inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the fina...
Signifor
(pasireotide)Orphan drugNovartis Pharmaceuticals Corporation
Somatostatin Analog [EPC]
12.1 Mechanism of Action SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding...
Gudmundur Johannsson, Professor
Vastra Gotaland Region, Sahlgrenska University Hospital
Shlomo Melmed, MD, M.D
Cedars-Sinai Medical Center, Pituitary Center
📍 LOS ANGELES, CA
Ho Sung Kim, MD PhD
Asan Medical Center
Irina Bancos, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Anne Klibanski, MD, MD
Massachusetts General Hospital
📍 BOSTON, MA
Stylianos Tsagarakis, Professor
Evaggelismos Hospital